Pfizer (NYSE:PFE) reported positive topline results from a Phase 3 study of its drug Braftovi, also known as encorafenib, in the treatment of a certain type of colorectal cancer. The study, called ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $150 billion and annual revenue exceeding $59 billion, announced today that its Phase 3 BREAKWATER study ...

The Board declared a quarterly dividend of $0.125 per share, payable on April 3, 2025 to shareholders of record on March 12, 2025.

As Valentine's Day celebrations approach, Hallmark is partnering with Kelsey Anderson to showcase perfect picks for all types of meaningful relationships. With a new selection of greeting cards and ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...